Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
  • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Definitions

• the present invention relates to the treatment of subjects having previously untreated follicular lymphoma (FL). More specifically, the invention pertains to combination treatment of subjects having previously untreated FL by administration of mosunetuzumab and lenalidomide.
• Cancers are characterized by the uncontrolled growth of cell subpopulations. Cancers are the leading cause of death in the developed world and the second leading cause of death in developing countries, with over 14 million new cancer cases diagnosed and over eight million cancer deaths occurring each year. Indolent cancers can also severely effect quality of life. Cancer care thus represents a significant and ever-increasing societal burden.
• B cell proliferative disorders are a leading cause of cancer-related deaths.
• NHL non-Hodgkin’s lymphoma
• NHL non-Hodgkin lymphoma
• FL Follicular lymphoma
• the present invention relates to methods of treating a subject having a previously untreated follicular lymphoma (FL) by administration of mosunetuzumab and lenalidomide as a combination therapy.
• the present invention relates to methods of treating a subject having a previously untreated FL by subcutaneous administration of mosunetuzumab and oral administration of lenalidomide.
• the invention features a method of treating a subject having a previously untreated follicular lymphoma (FL), the method comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day ( ⁇ 1 day) dosing cycle and a second 28-day ( ⁇ 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8 ( ⁇ 1 day), and 15 ( ⁇ 1 day), respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg (e.g., 5 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇
• the dosing regimen comprises one or more (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) additional dosing cycles. In some embodiments, the dosing regimen comprises one to ten (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10) additional dosing cycles. In some embodiments, the dosing regimen comprises ten additional dosing cycles. In some embodiments, the length of each of the one or more additional dosing cycles is about 28 days ( ⁇ 1 day).
• each of the one or more additional dosing cycles comprises an additional single dose of mosunetuzumab.
• the method comprises subcutaneously administering to the subject each additional single dose of mosunetuzumab on Day 1 of each of the one or more additional dosing cycles.
• the additional single dose of mosunetuzumab is about 45 mg (e.g., 45 mg ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, ⁇ 4 mg, ⁇ 5 mg, ⁇ 6 mg, ⁇ 7 mg, ⁇ 8 mg, or ⁇ 9 mg; e.g., 45 mg).
• each additional single dose of mosunetuzumab is about 45 mg (e.g., 45 mg ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, ⁇ 4 mg, ⁇ 5 mg, ⁇ 6 mg, ⁇ 7 mg, ⁇ 8 mg, or ⁇ 9 mg; e.g., 45 mg).
• lenalidomide is not administered during the first dosing cycle. In some embodiments, lenalidomide is orally administered during any of the one or more (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) additional dosing cycles. In some embodiments, lenalidomide is orally administered during each of the ten additional dosing cycles. In some embodiments, lenalidomide is orally administered on Days 1 -21 of each of the additional dosing cycles comprising administration of lenalidomide. In some embodiments, lenalidomide is not administered on the last 7 days ( ⁇ 1 day) of any dosing cycle comprising administration of lenalidomide.
• lenalidomide is administered at a dose of about 10 mg (e.g., 10 mg ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, or ⁇ 2 mg; e.g., 10 mg).
• lenalidomide is administered at a dose of about 20 mg (e.g., 20 mg ⁇ 0.05 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, or ⁇ 4 mg; e.g., 20 mg).
• the invention features a method of treating a subject having a previously untreated FL, the method comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day ( ⁇ 1 day) dosing cycle and a second 28-day ( ⁇ 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8 ( ⁇ 1 day), and 1 5 ( ⁇ 1 day), respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg (e.g., 5 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg
• the invention features a method of treating a subject having a previously untreated FL, the method comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day ( ⁇ 1 day) dosing cycle and a second 28-day ( ⁇ 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8 ( ⁇ 1 day), and 1 5 ( ⁇ 1 day), respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg (e.g., 5 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg
• the invention features a method of treating a subject having a previously untreated FL, the method comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day ( ⁇ 1 day) dosing cycle and eleven subsequent 28-day ( ⁇ 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8 ( ⁇ 1 day), and 15 ( ⁇ 1 day), respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg (e.g., 5 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, or
• the invention features a method of treating a subject having a previously untreated FL, the method comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day ( ⁇ 1 day) dosing cycle and eleven subsequent 28-day ( ⁇ 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8 ( ⁇ 1 day), and 15 ( ⁇ 1 day), respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg (e.g., 5 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, or
• the FL is histologically documented as Grade 1 , 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90).
• the subject has been previously determined based on the Groupe d'Etude des Lymphomes Fol liculai res (GELF) criteria (Brice et al. J Clin Oncol. 15(3) : 1110-1117, 1997) to be in need of systemic therapy to treat the previously untreated FL.
• GELF Groupe d'Etude des Lymphomes Fol liculai res
• the first dosing cycle further comprises administration of a corticosteroid.
• the second dosing cycle further comprises administration of a corticosteroid.
• any of the one or more additional dosing cycles comprises administration of a corticosteroid.
• a single dose of the corticosteroid is administered to the subject prior to the administration of any dose of mosunetuzumab.
• the corticosteroid comprises dexamethasone or methylprednisolone.
• the corticosteroid is administered intravenously or orally.
• the corticosteroid comprises dexamethasone and is administered at a dose of about 20 mg (e.g., 20 mg ⁇ 0.05 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, or ⁇ 4 mg; e.g., 20 mg).
• the corticosteroid comprises methylprednisolone and is administered at a dose of about 80 mg (e.g., 80 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, ⁇ 4 mg, ⁇ 5 mg, ⁇ 6 mg, ⁇ 7 mg, ⁇ 8 mg, ⁇ 10 mg, ⁇ 12 mg, ⁇ 14 mg, or ⁇ 16 mg; e.g., 80 mg).
• 80 mg e.g. 80 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇
• the first dosing cycle further comprises administration of an antihistamine.
• the second dosing cycle further comprises administration of an antihistamine.
• any of the one or more additional dosing cycles comprises administration of an antihistamine.
• a single dose of the antihistamine is administered to the subject prior to (e.g., 30, 35, 40, 45, 50, 60 70, 80, 90, 120, 150, 180 minutes, or more prior to) the administration of any dose of mosunetuzumab.
• the antihistamine is administered to the subject at least 30 minutes (e.g., 30, 35, 40, 45, 50, 60 70, 80, 90, 120, 150, 180 minutes, or more) prior to the administration of any dose of mosunetuzumab. In some embodiments, the antihistamine is administered orally or intravenously.
• the antihistamine comprises diphenhydramine hydrochloride and is administered at a dose of about 50-100 mg (e.g., 50-90 mg, 50-80 mg, 50-70 mg, 50-60 mg, 60-100 mg, 70-100 mg, 80-100 mg, 90-100 mg, 70- 80 mg, 60-90 mg, 60-80 mg, 70-90 mg, or 65-85 mg; e.g., about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, or about 100 mg).
• 50-100 mg e.g., 50-90 mg, 50-80 mg, 50-70 mg, 50-60 mg, 60-100 mg, 70-100 mg, 80-100 mg, 90-100 mg, 70- 80 mg, 60-90 mg, 60-80 mg, 70-90 mg, or 65-85 mg
• the first dosing cycle further comprises administration of an antipyretic.
• the second dosing cycle further comprises administration of an antipyretic.
• any of the one or more additional dosing cycles comprises administration of an anti-pyretic.
• a single dose of the anti-pyretic is administered to the subject prior to the administration of any dose of mosunetuzumab.
• the anti-pyretic is administered to the subject at least 30 minutes (e.g., 30, 35, 40, 45, 50, 60 70, 80, 90, 120, 150, 180 minutes, or more) prior to the administration of any dose of mosunetuzumab.
• the anti-pyretic is administered orally.
• the anti-pyretic comprises acetaminophen and is administered at a dose of about 500-1000 mg (e.g., 500-900 mg, 500- 800 mg, 500-700 mg, 500-600 mg, 600-1000 mg, 700-1000 mg, 800-1000 mg, 900-1000 mg, 700-800 mg, 600-900 mg, 600-800 mg, 700-900 mg, or 650-850 mg; e.g., about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg).
• 500-1000 mg e.g., 500-900 mg, 500- 800 mg, 500-700 mg, 500-600 mg, 600-1000 mg, 700-1000 mg, 800-1000 mg, 900-1000 mg, 700-800 mg, 600-900 mg, 600-800 mg, 700-900 mg, or 650-850 mg
• the first dosing cycle further comprises administration of an initial dose of a prophylactic agent against tumor lysis syndrome (TLS).
• the second dosing cycle further comprises administration of an initial dose of a prophylactic agent against TLS.
• any of the one or more additional dosing cycles comprises administration of an initial dose of a prophylactic agent against TLS.
• the initial dose of the prophylactic agent against TLS is administered to the subject prior to the administration of any dose of mosunetuzumab.
• the prophylactic agent against TLS comprises allopurinol.
• the initial dose of allopurinol is administered about 72 hours (e.g., 72 ⁇ 0.5 hours, ⁇ 1 hours, ⁇ 2 hours, ⁇ 3 hours, ⁇ 4 hours, ⁇ 8 hours, ⁇ 12 hours, or ⁇ 16 hours; e.g., 72 hours) prior to the administration of any dose of mosunetuzumab.
• additional single doses of allopurinol are administered daily for 6-10 days ( ⁇ 1 day) after the administration of the initial dose.
• the initial dose of allopurinol is about 300 mg (e.g., 300 mg ⁇ 5 mg, ⁇ 10 mg, ⁇ 15 mg, ⁇ 20 mg, ⁇ 25 mg, ⁇ 30 mg, ⁇ 45 mg, or ⁇ 60 mg; e.g., 300 mg).
• each additional single dose of allopurinol is about 300 mg (e.g., 300 mg ⁇ 5 mg, ⁇ 10 mg, ⁇ 15 mg, ⁇ 20 mg, ⁇ 25 mg, ⁇ 30 mg, ⁇ 45 mg, or ⁇ 60 mg; e.g., 300 mg).
• allopurinol is administered orally.
• the prophylactic agent against TLS comprises rasburicase.
• the initial dose of rasburicase is administered about 30 minutes (e.g., 30 ⁇ 0.5 minutes, 1 minutes, ⁇ 2 minutes, ⁇ 3 minutes, ⁇ 4 minutes, ⁇ 5 minutes, or ⁇ 6 minutes; e.g., 30 minutes) prior to the administration of any dose of mosunetuzumab.
• additional single doses of rasburicase are administered daily for 1 -5 days ( ⁇ 1 day) after the administration of the initial dose.
• the initial dose of rasburicase is about 0.2 mg/kg (e.g., 0.2 ⁇ 0.005 mg/kg, ⁇ 0.01 mg/kg, ⁇ 0.02 mg/kg, ⁇ 0.03 mg/kg, or ⁇ 0.04 mg/kg; e.g., 0.2 mg/kg).
• each additional single dose of rasburicase is about 0.2 mg/kg (e.g., 0.2 ⁇ 0.005 mg/kg, ⁇ 0.01 mg/kg, ⁇ 0.02 mg/kg, ⁇ 0.03 mg/kg, or ⁇ 0.04 mg/kg; e.g., 0.2 mg/kg).
• rasburicase is administered intravenously.
• FIG. 1 is a schematic of the study design described in Example 1 for the dosing regimen of the combination therapy of mosunetuzumab and lenalidomide.
• Mosunetuzumab is administered subcutaneously via injection and lenalidomide is administered orally.
• Len lenalidomide;
• Cycle dosing cycle.
• the present invention reiates to methods ot treating a subject having a previously untreated follicular lymphoma (FL) by administration of mosunetuzumab and lenalidomide as a combination therapy.
• Methods described herein comprise subcutaneously administering mosunetuzumab and orally administering lenalidomide to the subject according to a dosing regimen comprising at least a first dosing cycle and a second dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab, (b) the second dosing cycle comprises a first dose (C2D1 ) of mosunetuzumab and daily doses of lenalidomide.
• the first dosing cycle is a 21 -day ( ⁇ 1 day) dosing cycle and the C1 D1 , C1 D2, and C1 D3 doses are administered on or about Days 1 , 8 ( ⁇ 1 day), and 15 ( ⁇ 1 day), respectively
• the second dosing cycle is a 28-day ( ⁇ 1 day) dosing cycle and the C2D1 is administered on Day 1 .
• lenalidomide is administered on Days 1 -21 of the second dosing cycle.
• Methods of the invention additionally include administration of additional therapeutic agents, such as premedication (e.g., with a corticosteroid, an antihistamine, an anti-pyretic, or a prophylactic agent against tumor lysis syndrome (TLS)).
• premedication e.g., with a corticosteroid, an antihistamine, an anti-pyretic, or a prophylactic agent against tumor lysis syndrome (TLS)
• a “disorder” is any condition that would benefit from treatment including, but not limited to, chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question.
• cell proliferative disorder and “proliferative disorder” refer to disorders that are associated with some degree of abnormal cell proliferation.
• the cell proliferative disorder is cancer.
• the cell proliferative disorder is a tumor.
• cancer and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
• examples of cancer include, but are not limited to, hematologic cancers, such as mature B cell cancers, excluding Hodgkin’s lymphoma, but including non-Hodgkin’s lymphoma (NHL), such as diffuse large B cell lymphoma (DLBCL), which may be a Richter’s transformation.
• hematologic cancers such as mature B cell cancers, excluding Hodgkin’s lymphoma, but including non-Hodgkin’s lymphoma (NHL), such as diffuse large B cell lymphoma (DLBCL), which may be a Richter’s transformation.
• NHL non-Hodgkin’s lymphoma
• DLBCL diffuse large B cell lymphoma
• cancer also include germinal-center B cell-like (GCB) diffuse large B cell lymphoma (DLBCL), activated B cell-like (ABC) DLBCL, follicular lymphoma (FL), transformed FL, mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), transformed MZL, high grade B-cell lymphoma, primary mediastinal (thymic) large B cell lymphoma (PMLBCL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), transformed LL, Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt’s lymphoma (BL), B cell prolymphocytic leukemia, splenic marginal zone lymphoma, hairy cell leukemia, splenic lymphoma/leukemia, unclassifiable,
• cancers include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies, including B cell lymphomas. More particular examples of such cancers include, but are not limited to, multiple myeloma (MM); low-grade/follicular NHL; small lymphocytic (SL) NHL; intermediate-grade/follicular NHL; intermediate-grade diffuse NHL; high-grade immunoblastic NHL; high-grade lymphoblastic NHL; high-grade small non-cleaved cell NHL; bulky disease NHL; AIDS-related lymphoma; and acute lymphoblastic leukemia (ALL); chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD).
• MM multiple myeloma
• SL small lymphocytic
• NHL intermediate-grade/follicular NHL
• intermediate-grade diffuse NHL high-grade immunoblastic NHL
• high-grade lymphoblastic NHL high-grade small non-clea
• Tumor refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
• cancer refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
• cancer refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells
• B cell proliferative disorder refers to disorders that are associated with some degree of abnormal B cell proliferation and include, for example, lymphomas, leukemias, myelomas, and myelodysplastic syndromes.
• the B cell proliferative disorder is a lymphoma, such as non-Hodgkin’s lymphoma (NHL), including, for example, follicular lymphoma (FL) (e.g., a previously untreated FL).
• NHL non-Hodgkin’s lymphoma
• FL follicular lymphoma
• a subject having a previously untreated FL has been determined based on the Groupe d'Etude des Lymphomes Fol liculai res (GELF) criteria (Brice et al. J Clin Oncol. 15(3) : 1110-1117, 1997) to be in need of systemic therapy to treat the previously untreated FL.
• GELF Groupe d'Etude des Lymphomes Fol liculai re
• Groupe d'Etude des Lymphomes Folliismes criteria and “GELF criteria” refer to criteria for determining whether immediate therapy for follicular lymphoma is required. In particular, a subject or individual satisfying one of more GELF criteria is determined to be in need of treatment.
• GELF criteria include (i) any nodal or extranodal tumor mass > 7 cm in diameter; (ii) involvement of at least 3 nodal sites, each with diameter > 3 cm; (iii) presence of type B symptoms (e.g., fever, night sweats, and weight loss); (iv) splenomegaly (> 16 cm on computer tomography (CT) scan); (v) risk of local compressive symptoms that may result in organ compromise; (vi) pleural effusion or peritoneal ascites; (vii) leukemic phase (> 5 x 10 9 /L circulating malignant cells); and (viii) cytopenia (granulocye count ⁇ 1 x 10 9 /L and/or platelets ⁇ 100 x 10 9 /L). See Brice et al. J Clin Oncol.
• a subject satisfying one or more GELF criteria is considered to have a high tumor burden.
• FLIPI Fibricular Lymphoma International Prognostic Index
• a scoring system or index for determining prognostic risk of patients e.g., with cancer; e.g., an NHL; e.g., a follicular lymphoma (FL)
• FLIPI score ranges from 0-5, depending on how many of the five conditions or risk factors a patient may have among the following: (i) age > 60 years; (ii) Ann Arbor stage lll-IV; hemoglobin level ⁇ 120 g/L; serum lactate dehydrogenase (LDH) level > upper limit of normal (ULN) (e.g., > 280 units/L); and (v) number of nodal sites > 4.
• annul Arbor staging refers to a system for classification of stages of lymphoma (e.g., NHL, e.g., FL, e.g., previously untreated FL). Lymphomas (e.g., NHLs) can be classified as one of four Ann Arbor stages. Stage I refers to lymphomas exhibiting involvement of a single lymph node region or of a single extralymphatic organ or site. Stage II refers to lymphomas exhibiting involvement of 2 or more lymph node regions on the same side of the diaphragm.
• lymphoma e.g., NHL, e.g., FL, e.g., previously untreated FL.
• Lymphomas e.g., NHLs
• Stage I refers to lymphomas exhibiting involvement of a single lymph node region or of a single extralymphatic organ or site.
• Stage II refers to lymphomas exhibiting involvement of 2 or more lymph node regions on the same side of the diaphragm.
• Stage III refers to lymphomas exhibiting involvement of lymph node regions on both sides of the diaphragm (III), which may also be accompanied by localized involvement of extralymphatic organ or site or by involvement of the spleen, or both.
• Stage IV refers to lymphomas exhibiting diffuse or disseminated involvement of 1 or more extralymphatic organs or tissues with or without associated lymph node enlargement. Liver involvement is always considered to be diffuse, and, thus, always considered Ann Arbor stage IV. Lymphatic structures include the lymph nodes, thymus, spleen, appendix, Waldeyer’s ring, and Peyer’s patches. See Carbone, P.P. et al., Cancer Res. 1971 , 31 (11 ):1860-1861 .
• treatment refers to clinical intervention in an attempt to alter the natural course of the subject being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.
• antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.
• “delaying progression” of a disorder or disease means to defer, hinder, slow, retard, stabilize, and/or postpone development of the disease or disorder (e.g., a previously untreated FL). This delay can be of varying lengths of time, depending on the history of the disease and/or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease. For example, a latestage cancer, such as development of metastasis, may be delayed.
• extending survival is meant increasing overall or progression free survival in a treated patient relative to an untreated patient (e.g., relative to a patient not treated with the medicament), or relative to a patient who does not express a biomarker at the designated level, and/or relative to a patient treated with an approved anti-tumor agent.
• An objective response refers to a measurable response, including complete response (CR) or partial response (PR).
• reduce or “inhibit” is meant the ability to cause an overall decrease, for example, of 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or greater.
• reduce or “inhibit” is meant the ability to cause an overall decrease, for example, of 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or greater.
• the term includes also reduction to zero (or below the detection limit of the analytical method), i.e., complete abolishment or elimination.
• reduce or inhibit can refer to the reduction or inhibition of undesirable events, such as cytokine-driven toxicities (e.g., cytokine release syndrome (CRS)), infusion- related reactions (IRRs), macrophage activation syndrome (MAS), neurologic toxicities, severe tumor lysis syndrome (TLS), neutropenia, thrombocytopenia, elevated liver enzymes, and/or central nervous system (CNS) toxicities, following treatment with mosunetuzumab using the step-up dosing regimen of the invention relative to unchanging, preset dosing with the target dose of mosunetuzumab.
• undesirable events such as cytokine-driven toxicities (e.g., cytokine release syndrome (CRS)), infusion- related reactions (IRRs), macrophage activation syndrome (MAS), neurologic toxicities, severe tumor lysis syndrome (TLS), neutropenia, thrombocytopenia, elevated liver enzymes, and/or central nervous system (CNS) toxicities
• CRS central nervous system
• reduce or inhibit can refer to effector function of an antibody that is mediated by the antibody Fc region, such effector functions specifically including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).
• reduce or inhibit can refer to the symptoms of the previously untreated FL being treated, the presence or size of metastases, or the size of the primary tumor.
• reducing or inhibiting cancer relapse means to reduce or inhibit tumor or cancer relapse, or tumor or cancer progression (e.g., reduce the risk of or prevent progression and/or relapse of the FL).
• administering is meant a method of giving a dosage of a compound (e.g., a bispecific antibody, e.g., an anti-CD20/anti-CD3 bispecific antibody, e.g., mosunetuzumab; e.g., a corticosteroid, antihistamine, anti-pyretic, interleukin-6 receptor (IL-6R) antagonist, or prophylactic agent against tumor lysis syndrome (TLS)) or a composition (e.g., a pharmaceutical composition, e.g., a pharmaceutical composition including a bispecific antibody (e.g., mosunetuzumab) or other therapeutic agent) to a subject.
• a compound e.g., a bispecific antibody, e.g., an anti-CD20/anti-CD3 bispecific antibody, e.g., mosunetuzumab; e.g., a corticosteroid, antihistamine, anti-pyretic, interleukin-6 receptor (
• a “fixed” or “flat” dose of a therapeutic agent herein refers to a dose that is administered to a patient without regard for the weight or body surface area (BSA) of the patient.
• the fixed or flat dose is therefore not provided as a mg/kg dose or a mg/m 2 dose, but rather as an absolute amount of the therapeutic agent (e.g., mg).
• a “subject” or an “individual” is a mammal. Mammals include, but are not limited to, primates (e.g., humans and non-human primates such as monkeys), domesticated animals (e.g., cows, sheep, cats, dogs, and horses), rabbits, and rodents (e.g., mice and rats). In a particular embodiment, the subject or individual is a human.
• primates e.g., humans and non-human primates such as monkeys
• domesticated animals e.g., cows, sheep, cats, dogs, and horses
• rabbits e.g., mice and rats
• rodents e.g., mice and rats
• “Individual response” or “response” can be assessed using any endpoint indicating a benefit to the subject, including, without limitation, (1 ) inhibition, to some extent, of disease progression (e.g., progression of a previously untreated FL, including slowing down and complete arrest; (2) a reduction in tumor size; (3) inhibition (i.e., reduction, slowing down or complete stopping) of cancer cell infiltration into adjacent peripheral organs and/or tissues; (4) inhibition (i.e., reduction, slowing down or complete stopping) of metastasis; (5) relief, to some extent, of one or more symptoms associated with the previously untreated FL; (6) increase or extend in the length of survival, including overall survival and progression-free survival; and/or (9) decreased mortality at a given point of time following treatment.
• response to treatment of a previously untreated FL is evaluated using the Lugano response criteria for malignant lymphoma (Cheson BD, et al. J Clin Oncol 2014; 32:1 -9).
• Lugano Criteria or “Lugano Response Criteria” for malignant lymphoma, as used herein, are a set of criteria for evaluating response assessments (e.g., of PET/CT scans) to the methods of treatment described herein.
• the Lugano Criteria is described below in Table 1 : Table 1. Lugano Response Criteria for Malignant Lymphoma Response Assessment
• 5PS 5-point scale
• CT computed tomography
• FDG fluorodeoxyglucose
• IHC immunohistochemistry
• LDi longest transverse diameter of a lesion
• MRI magnetic resonance imaging
• PET positron emission tomography
• PPD cross product of the LDi and perpendicular diameter
• SDi shortest axis perpendicular to the LDi
• SPD sum of the product of the perpendicular diameters for multiple lesions.
• Measured dominant lesions Up to six of the largest dominant nodes, nodal masses, and extranodal lesions selected to be clearly measurable in two diameters. Nodes should preferably be from disparate regions of the body and should include, where applicable, mediastinal and retroperitoneal areas. Non-nodal lesions include those in solid organs (e.g., liver, spleen, kidneys, lungs), gastrointestinal involvement, cutaneous lesions, or those noted on palpation. Non-measured lesions: Any disease not selected as measured; dominant disease and truly assessable disease should be considered not measured.
• sites include any nodes, nodal masses, and extranodal sites not selected as dominant or measurable or that do not meet the requirements for measurability but are still considered abnormal, as well as truly assessable disease, which is any site of suspected disease that would be difficult to follow quantitatively with measurement, including pleural effusions, ascites, bone lesions, leptomeningeal disease, abdominal masses, and other lesions that cannot be confirmed and followed by imaging.
• FDG uptake may be greater than in the mediastinum with complete metabolic response, but should be no higher than surrounding normal physiologic uptake (e.g., with marrow activation as a result of chemotherapy or myeloid growth factors).
• target lesions include up to six of the largest target nodes, nodal masses, or other lymphomatous lesions that are measurable in two diameters should be identified from different body regions representative of the patient’s overall disease burden and include mediastinal and retroperitoneal disease, if involved.
• a measurable node must be greater than 15 mm in longest diameter (LDi).
• Measurable extranodal disease may be included in the six representative, measured lesions.
• measurable extranodal lesions should be greater than 10 mm LDi.
• All other lesions should be followed as non-measured disease as non-target lesions (e.g., cutaneous, gastrointestinal, bone, spleen, liver, kidneys, pleural or pericardial effusions, ascites, bone, bone marrow).
• Lesions may split or may become confluent over time.
• the individual product of the perpendicular diameters (PPDs) of the nodes should be summed together to represent the PPD of the split lesion; this PPD is added to the sum of the PPDs of the remaining lesions to measure response.
• the nadir of each individual node is used to determine progression.
• the PPD of the confluent mass should be compared with the sum of the PPDs of the individual nodes, with more than 50% increase in PPD of the confluent mass compared with the sum of individual nodes necessary to indicate progressive disease.
• the LDi and smallest diameter (SDi) are no longer needed to determine progression.
• ORR objective response rate
• DOR duration of objective response
• DDR delay of complete response
• tumor burden refers to the total amount of tumor (e.g., tumor cells or tumor mass) in a subject (e.g., a human subject) having a cancer, e.g., an NHL, e.g., an FL.
• tumor burden is defined as the sum of diameters of target lesions or the sum of the product of target lesions.
• tumor burden is defined as the sum of the product of the diameters of (SPD) target lesions.
• the diameters of target lesions is quantified by computed tomography (CT).
• sustained response refers to the sustained effect on reducing tumor growth after cessation of a treatment.
• the tumor size may remain to be the same or smaller as compared to the size at the beginning of the administration phase.
• the sustained response has a duration at least the same as the treatment duration, at least 1 .5x, 2. Ox, 2.5x, or 3. Ox length of the treatment duration.
• an “effective response” of a subject or a subject’s “responsiveness” to treatment with a medicament and similar wording refers to the clinical or therapeutic benefit imparted to a subject as risk for, or suffering from, a disease or disorder, such as cancer.
• a disease or disorder such as cancer.
• such benefit includes any one or more of: extending survival (including overall survival and progression free survival); resulting in an objective response (including a complete response or a partial response); or improving signs or symptoms of cancer.
• a subject who “does not have an effective response” to treatment refers to a subject who does not have any one of extending survival (including overall survival and progression free survival); resulting in an objective response (including a complete response or a partial response); or improving signs or symptoms of cancer.
• survival refers to the patient remaining alive, and includes overall survival as well as progression-free survival.
• overall survival refers to the percentage of subjects in a group who are alive after a particular duration of time, e.g., 1 year or 5 years from the time of diagnosis or treatment.
• progression-free survival refers to the length of time during and after treatment during which the disease being treated (e.g., a previously untreated FL) does not get worse. Progression-free survival may include the amount of time patients have experienced a complete response or a partial response, as well as the amount of time patients have experienced stable disease.
• antibody herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
• antibody fragment refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds.
• antibody fragments include but are not limited to Fv, Fab, Fab’, Fab’-SH, F(ab’)2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.
• full-length antibody “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
• cluster of differentiation 3 refers to any native CD3 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated, including, for example, CD3s, CD3y, CD3a, and CD3p chains.
• the term encompasses “full-length,” unprocessed CD3 (e.g., unprocessed or unmodified CD3s or CD3y), as well as any form of CD3 that results from processing in the cell.
• the term also encompasses naturally occurring variants of CD3, including, for example, splice variants or allelic variants.
• CD3 includes, for example, human CD3E protein (NCBI RefSeq No. NP_000724), which is 207 amino acids in length, and human CD3y protein (NCBI RefSeq No. NP_000064), which is 182 amino acids in length.
• human CD3E protein NCBI RefSeq No. NP_000724
• human CD3y protein NCBI RefSeq No. NP_000064
• cluster of differentiation 20 refers to any native CD20 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated.
• the term encompasses “full-length,” unprocessed CD20, as well as any form of CD20 that results from processing in the cell.
• the term also encompasses naturally occurring variants of CD20, including, for example, splice variants or allelic variants.
• CD20 includes, for example, human CD20 protein (see, e.g., NCBI RefSeq Nos.
• NP_068769.2 and NP_690605.1 which is 297 amino acids in length and may be generated, for example, from variant mRNA transcripts that lack a portion of the 5’ UTR (see, e.g., NCBI RefSeq No. NM_021950.3) or longer variant mRNA transcripts (see, e.g., NCBI RefSeq No. NM_152866.2).
• anti-CD20/anti-CD3 bispecific antibody refers to mosunetuzumab.
• mosunetuzumab refers to an anti-CD20/anti-CD3 bispecific antibody having the International Nonproprietary Names for Pharmaceutical Substances (INN) List 117 (WHO Drug Information, Vol. 31 , No. 2, 2017, p. 304-305), or the CAS Registry Number 1905409-39-3.
• the term “lenalidomide” refers to a compound having the CAS Registry Number 191732-72-6 and IUPAC name (3RS)-3-(4-Amino-1 -oxo-1 ,3-dihydro-2H-isoindol-2-yl)piperidine-2, 6-dione.
• Lenalidomide is also known by tradenames including REVLIMID®, linamid, and lenalid.
• Lenalidomide has the DrugBank Accession Number DB00480, PubChem CID 216326, and chemical formula C13H13N3O3.
• the term “binds,” “specifically binds to,” or is “specific for” refers to measurable and reproducible interactions such as binding between a target and an antibody, which is determinative of the presence of the target in the presence of a heterogeneous population of molecules including biological molecules.
• an antibody that specifically binds to a target (which can be an epitope) is an antibody that binds this target with greater affinity, avidity, more readily, and/or with greater duration than it binds to other targets.
• the extent of binding of an antibody to an unrelated target is less than about 10% of the binding of the antibody to the target as measured, for example, by a radioimmunoassay (RIA).
• an antibody that specifically binds to a target has a dissociation constant (KD) of ⁇ 1 pM, ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, or ⁇ 0.1 nM.
• KD dissociation constant
• an antibody specifically binds to an epitope on a protein that is conserved among the protein from different species.
• specific binding can include, but does not require exclusive binding.
• the term as used herein can be exhibited, for example, by a molecule having a KD for the target of 10 -4 M or lower, alternatively 10 -5 M or lower, alternatively 10 -6 M or lower, alternatively 10 -7 M or lower, alternatively 10 -8 M or lower, alternatively 10 -9 M or lower, alternatively 10 -10 M or lower, alternatively 10 -11 M or lower, alternatively 10 -12 M or lower or a KD in the range of 10 -4 M to 10 -6 M or 10 -6 M to 10 -10 M or 10 -7 M to 10 -9 M.
• affinity and KD values are inversely related. A high affinity for an antigen is measured by a low KD value.
• the term “specific binding” refers to binding where a molecule binds to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.
• pharmaceutical formulation refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
• a “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject.
• a pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
• chemotherapeutic agent refers to a compound useful in the treatment of a cancer, such as a previously untreated FL.
• chemotherapeutic agents include EGFR inhibitors (including small molecule inhibitors (e.g., erlotinib (TARCEVA®, Genentech/OSI Pharm.); PD 183805 (Cl 1033, 2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6- quinazolinyl]-, dihydrochloride, Pfizer Inc.); ZD1839, gefitinib (IRESSA®) 4-(3’-Chloro-4’-fluoroanilino)-7- methoxy-6-(3-morpholinopropoxy)quinazoline, AstraZeneca); ZM 105180 ((6-amino-4-(3-methylphenyl- amino)-
• Chemotherapeutic agents also include (i) anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX®; tamoxifen citrate), raloxifene, droloxifene, iodoxyfene, 4- hydroxytamoxifen, trioxifene, keoxifene, LY1 17018, onapristone, and FARESTON® (toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE® (megestrol acetate), AROMASIN® (exemestane; Pfizer), formestanie, fadrozole, RIVISOR® (vorozole), FEMARA® (
• chemo-immunotherapy refers to combination therapy that includes both chemotherapy drugs and immunotherapeutic agents.
• chemo-immunotherapy is used to treat a cancer, e.g., a CD20-positive cancer, e.g., a NHL, e.g., a FL.
• immunotherapeutic agents include an antibody, e.g., an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody).
• the anti-CD20 antibody or anti-CD20 monoclonal antibody is rituximab or obinutuzumab.
• chemo-immunotherapy includes R-CHOP.
• Cytotoxic agent refers to any agent that is detrimental to cells (e.g., causes cell death, inhibits proliferation, or otherwise hinders a cellular function).
• Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., 211 At, 131 l, 125 l, 90 Y, 186 Re, 188 Re, 153 Sm, 212 Bi, 32 P, 212 Pb, and radioactive isotopes of Lu); chemotherapeutic agents; enzymes and fragments thereof such as nucleolytic enzymes; and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof.
• radioactive isotopes e.g., 211 At, 131 l, 125 l, 90 Y, 186 Re, 188 Re, 153 Sm, 212 Bi, 32 P, 212 Pb, and radioactive isotopes of Lu
• Exemplary cytotoxic agents can be selected from anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, inhibitors of LDH-A, inhibitors of fatty acid biosynthesis, cell cycle signaling inhibitors, HDAC inhibitors, proteasome inhibitors, and inhibitors of cancer metabolism.
• the cytotoxic agent is a platinum-based chemotherapeutic agent (e.g., carboplatin or cisplatin).
• the cytotoxic agent is an antagonist of EGFR, e.g., N-(3- ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (e.g., erlotinib).
• the cytotoxic agent is a RAF inhibitor, e.g., a BRAF and/or CRAF inhibitor.
• the RAF inhibitor is vemurafenib.
• the cytotoxic agent is a PI3K inhibitor.
• package insert is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.
• the present invention relates to methods of treating a subject having a 1/L FL by subcutaneous administration of mosunetuzumab and oral administration of lenalidomide.
• the FL is a Graded FL (e.g., Grade 1 , 2, or 3a, but not Grade 3b FL).
• the FL of each subject is histologically documented as Grade 1 , 2, or 3a, but not 3b, according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90).
• the subject has not been treated with any standard or investigational anticancer therapy, including, but not limited to: (i) lenalidomide exposure within 12 months prior to administration of the first dose of mosunetuzumab (e.g., C1 D1 dose) of the methods of the invention; (ii) fludarabine or alemtuzumab within 12 months prior to administration of the first dose of mosunetuzumab (e.g., C1 D1 dose) of the methods of the invention; (iii) radioimmunoconjugate within 12 weeks prior to administration of the first dose of mosunetuzumab (e.g., C1 D1 dose) of the methods of the invention; (iv) prior anti-lymphoma treatment with monoclonal antibody or antibody-drug conjugate within 4 weeks prior to administration of the first dose of mosunetuzumab (e.g., C1 D1 dose) of the methods of the invention; and (v) treatment with any chemotherapeutic
• the subject has been previously determined based on the Groupe d'Etude des Lymphomes Fol liculai res (GELF) criteria (Brice et al. J Clin Oncol. 15(3) : 1110-1117, 1997) to be in need of systemic therapy to treat the previously untreated FL.
• GELF Groupe d'Etude des Lymphomes Fol liculai res
• the present invention reiates to methods ot treating a subject having a previously untreated follicular lymphoma (FL) by administration of mosunetuzumab and lenalidomide as a combination therapy.
• the present invention relates to methods of treating a subject having a previously untreated FL by subcutaneous administration of mosunetuzumab and oral administration of lenalidomide.
• the invention features a method of treating a subject having a previously untreated follicular lymphoma (FL), the method comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day ( ⁇ 1 day) dosing cycle and a second 28-day ( ⁇ 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8 ( ⁇ 1 day), and 15 ( ⁇ 1 day), respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg (e.g., 5 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇
• the dosing regimen comprises one or more (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) additional dosing cycles. In some embodiments, the dosing regimen comprises one to ten (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10) additional dosing cycles. In some embodiments, the dosing regimen comprises ten additional dosing cycles. In some embodiments, the length of any of the one or more additional dosing cycles is about 28 days ( ⁇ 1 day). In some embodiments, the length of each of the one or more additional dosing cycles is about 28 days ( ⁇ 1 day).
• any of the one or more additional dosing cycles comprises an additional single dose of mosunetuzumab.
• each of the one or more additional dosing cycles comprises an additional single dose of mosunetuzumab.
• the method comprises subcutaneously administering to the subject each additional single dose of mosunetuzumab on Day 1 of each of the one or more additional dosing cycles.
• the additional single dose of mosunetuzumab is about 45 mg (e.g., 45 mg ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, ⁇ 4 mg, ⁇ 5 mg, ⁇ 6 mg, ⁇ 7 mg, ⁇ 8 mg, or ⁇ 9 mg; e.g., 45 mg).
• each additional single dose of mosunetuzumab is about 45 mg (e.g., 45 mg ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, ⁇ 4 mg, ⁇ 5 mg, ⁇ 6 mg, ⁇ 7 mg, ⁇ 8 mg, or ⁇ 9 mg; e.g., 45 mg).
• lenalidomide is not administered during the first dosing cycle. In some embodiments, lenalidomide is orally administered during any of the one or more (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) additional dosing cycles. In some embodiments, lenalidomide is orally administered during any of the ten additional dosing cycles. In some embodiments, lenalidomide is orally administered during each of the ten additional dosing cycles. In some embodiments, lenalidomide is orally administered on Days 1 -21 of each of the additional dosing cycles comprising administration of lenalidomide. In some embodiments, lenalidomide is not administered on the last
• lenalidomide is administered at a dose of about 10 mg (e.g., 10 mg ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, or ⁇ 2 mg; e.g., 10 mg).
• lenalidomide is administered at a dose of about 20 mg (e.g., 20 mg ⁇ 0.05 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, or ⁇ 4 mg; e.g., 20 mg).
• the invention features a method of treating a subject having a previously untreated FL, the method comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day ( ⁇ 1 day) dosing cycle and a second 28-day ( ⁇ 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 ,
• the C1 D1 is about 5 mg (e.g., 5 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, or ⁇ 1 mg; e.g., 5 mg)
• the C1 D2 is about 45 mg (e.g., 45 mg ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, ⁇ 4 mg, ⁇ 5 mg, ⁇ 6 mg, ⁇ 7 mg, ⁇ 8 mg, or ⁇ 9 mg; e.g., 45 mg)
• the C1 D3 is about 45 mg (e.g., 45 mg ⁇
• the invention features a method of treating a subject having a previously untreated FL, the method comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day ( ⁇ 1 day) dosing cycle and a second 28-day ( ⁇ 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8 ( ⁇ 1 day), and 15 ( ⁇ 1 day), respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg (e.g., 5 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg,
• the invention features a method of treating a subject having a previously untreated FL, the method comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day ( ⁇ 1 day) dosing cycle and eleven subsequent 28-day ( ⁇ 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8 ( ⁇ 1 day), and 15 ( ⁇ 1 day), respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg (e.g., 5 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, or
• the invention features a method of treating a subject having a previously untreated FL, the method comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day ( ⁇ 1 day) dosing cycle and eleven subsequent 28-day ( ⁇ 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8 ( ⁇ 1 day), and 15 ( ⁇ 1 day), respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg (e.g., 5 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, or
• the FL is histologically documented as Grade 1 , 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90).
• the subject has been previously determined based on the Groupe d'Etude des Lymphomes Fol liculai res (GELF) criteria (Brice et al. J Clin Oncol. 15(3) : 1110-1117, 1997) to be in need of systemic therapy to treat the previously untreated FL.
• GELF Groupe d'Etude des Lymphomes Fol liculai res
• the subject is human.
• mosunetuzumab and lenalidomide are formulated, dosed, and administered in a fashion consistent with good medical practice.
• Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual subject, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
• Mosunetuzumab and lenalidomide need not be, but are optionally formulated with, administered in combination with, or used with one or more additional agents (e.g., therapeutic agents) currently used to prevent or treat the disorder in question and/or reduce the rate of, reduce the severity of, treat, or prevent adverse events and/or symptoms associated with the adverse events.
• the effective amount of such other agents depends on the amount of mosunetuzumab and/or lenalidomide present in the formulation, the type of disorder or treatment, the type of adverse event, and other factors discussed herein.
• Mosunetuzumab and lenalidomide may be suitably administered to the subject over a series of treatments. When mosunetuzumab and lenalidomide are administered on the same day, lenalidomide is administered to the subject prior to administration of mosunetuzumab.
• the present invention relates to methods of treating a subject having a previously untreated follicular lymphoma (FL) by administration of mosunetuzumab and lenalidomide as a combination therapy, in some embodiments, therapies and dosing regimens described herein provide acceptable safety profiles in subjects with previously untreated FL treated with the described dosing regimens.
• FL follicular lymphoma
• Any of the methods described herein may involve monitoring a subject for cytokine release syndrome (CRS), e.g., a CRS event following commencement of any of the methods described above.
• CRS cytokine release syndrome
• Current clinical management focuses on treating the individual signs and symptoms, providing supportive care, and attempting to dampen the inflammatory response using a high dose of corticosteroids. However, this approach is not always successful, especially in the case of late intervention.
• the CRS grading criteria used by the methods described herein are published by the American Society for Transplantation and Cellular Therapy (ASTCT) to define mild, moderate, severe, or life-threatening CRS and harmonize reporting across clinical trials to allow rapid recognition and treatment of CRS (Lee et al. Biol Blood Marrow Transplantation. 25(4): 625-638, 2019).
• the ASTCT criteria is intended to be objective, easy to apply, and more accurately categorize the severity of CRS. This CRS grading system is shown below in Table 2.
• ASTCT American Society for Transplantation and Cellular Therapy
• BiPAP bilevel positive airway pressure
• CPAP continuous positive airway pressure
• CRS cytokine release syndrome
• CTCAE Common Terminology Criteria for Adverse Events.
• Fever is defined as a temperature > 38 °C not attributable to any other cause.
• subjects who have CRS then receive antipyretic or anticytokine therapy such as tocilizumab or corticosteroids, fever is no longer required to grade subsequent CRS severity.
• CRS grading is determined by hypotension and/or hypoxia.
• CRS grade is determined by the more severe event, hypotension or hypoxia not attributable to any other cause. For example, a subject with temperature of 39.5 °C, hypotension requiring 1 vasopressor, and hypoxia requiring low-flow nasal cannula is classified as Grade 3 CRS.
• Low-flow nasal cannula is defined as oxygen delivered at ⁇ 6 L/minute. Low flow also includes blow-by oxygen delivery, sometimes used in pediatrics. High-flow nasal cannula is defined as oxygen delivered at > 6 L/minute.
• CRS is associated with elevations in a wide array of cytokines, including marked elevations in
• IL-6 is a proinflammatory, multi-functional cytokine produced by a variety of cell types, which has been shown to be involved in a diverse array of physiological processes, including T cell activation. Regardless of the inciting agent, CRS is associated with high IL-6 levels (Nagorsen et al. Cytokine. 25(1 ): 31 -5, 2004; Lee et al. Blood. 124(2): 188-95, 2014); Doesegger et al. Clin. Transl. Immunology.
• IL-6 correlates with the severity of CRS, with subjects who experience a Grade 4 or 5 CRS event having much higher IL-6 levels compared to subjects who do not experience CRS or experience milder CRS (Grades 0-3) (Chen et al. J. Immunol. Methods. 434:1 -8, 2016).
• the method may further comprise administering to the subject one or more additional doses of the IL-6R antagonist to manage the CRS event.
• the subject may be administered a corticosteroid, such as methylprednisolone or dexamethasone if CRS event is not managed through administration of the IL-6R antagonist.
• any of the methods described herein may involve monitoring a subject for additional non-CRS adverse events. Incidence, nature, and severity of physical findings and adverse events, with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5 (NCI CTCAE v5.0). Other than CRS, one of the most common adverse events reported in patients undergoing treatment with mosunetuzumab and/or lenalidomide is neutropenia (e.g., febrile neutropenia).
• neutropenia e.g., febrile neutropenia
• Neutropenia is characterized by an abnormally low blood count of neutrophils, which are a type of white blood cells. Neutropenia may lead to an increased risk of infection.
• the generally accepted reference range for absolute neutrophil count (ANC) in adult humans is 1 ,500 to 8,000 cells/pL of blood.
• Mild neutropenia is characterized by ANC between 1 ,000-1 ,500 cells/pL (Grade 1 -2);
• moderate neutropenia is characterized by ANC between 500 and 1 ,000 cells/pL (Grade 3)
• severe neutropenia is characterized by ANC below 500 cells/pL (Grade 4).
• Febrile neutropenia (Grade 3+ neutropenia) is characterized by ANC below 1 ,000 cells/pL in addition to either a single temperature measurement greater than 38.3 °C or sustained temperature measurements greater than 38 °C for more than one hour.
• TLS Tumor lysis syndrome
• TLS tumor lysis syndrome
• ULN upper limit of normal. Note: TLS should be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0.
• Acute kidney injury is defined as an increase of 0.3 mg/dL (26.5 pmol/L) in creatinine level or a period of oliguria lasting 6 or more hours. By definition, if acute kidney injury is present, the patient has clinical TLS (Levin et al. Am. J. Kidney Dis. 50(1 ):1 -4, 2007).
• mosunetuzumab and lenalidomide have the potential for B-cell killing, the potential risk of TLS in all patients must be considered, along with the need for prophylaxis for TLS prior to the initiation of mosunetuzumab.
• IV hydration at a rate of 150-200 mL/hour should begin at the conclusion of mosunetuzumab administration and continue for at least 24 hours thereafter.
• fluid intake should be maintained at approximately 2-3 L/day for at least 24 hours after mosunetuzumab administration.
• Allopurinol e.g., 300 mg/day orally beginning 72 hours prior to dose and continuing for 3-7 days afterward
• rasburicase e.g., 0.2 mg/kg IV over 30 minutes prior to first dose mosunetuzumab and daily for up to 5 days thereafter
• contraindicated Elitek® [rasburicase] U.S. Package Insert
• TLS patients at high risk for TLS should continue to receive prophylaxis with allopurinol or rasburicase and adequate hydration with each subsequent dose of mosunetuzumab and lenalidomide until the patient is no longer considered to be at risk for TLS. Patients who develop either clinical or laboratory TLS during Cycle 1 should be considered for hospitalization during subsequent cycles for optimum hydration and monitoring.
• the Howard criteria for TLS are fulfilled at any time during the study (two or more electrolyte laboratory abnormalities present simultaneously) or if there is a medically relevant laboratory abnormality in TLS-related parameters or a sign of clinical TLS (e.g., increased serum creatinine or cardiac dysrhythmia), study treatment should be withheld and patients should be hospitalized and adequately treated until normalization of laboratory abnormalities before study treatment is restarted.
• the invention features a method of treating a subject having a previously untreated follicular lymphoma (FL), the method comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day ( ⁇ 1 day) dosing cycle and a second 28-day ( ⁇ 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8 ( ⁇ 1 day), and 15 ( ⁇ 1 day), respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg (e.g., 5 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇
• the dosing regimen comprises one or more (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) additional dosing cycles. In some embodiments, the dosing regimen comprises one to ten (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10) additional dosing cycles. In some embodiments, the dosing regimen comprises ten additional dosing cycles. In some embodiments, the length of any of the one or more additional dosing cycles is about 28 days ( ⁇ 1 day). In some embodiments, the length of each of the one or more additional dosing cycles is about 28 days ( ⁇ 1 day).
• any of the one or more additional dosing cycles comprises an additional single dose of mosunetuzumab.
• each of the one or more additional dosing cycles comprises an additional single dose of mosunetuzumab.
• the method comprises subcutaneously administering to the subject each additional single dose of mosunetuzumab on Day 1 of each of the one or more additional dosing cycles.
• the additional single dose of mosunetuzumab is about 45 mg (e.g., 45 mg ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, ⁇ 4 mg, ⁇ 5 mg, ⁇ 6 mg, ⁇ 7 mg, ⁇ 8 mg, or ⁇ 9 mg; e.g., 45 mg).
• each additional single dose of mosunetuzumab is about 45 mg (e.g., 45 mg ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, ⁇ 4 mg, ⁇ 5 mg, ⁇ 6 mg, ⁇ 7 mg, ⁇ 8 mg, or ⁇ 9 mg; e.g., 45 mg).
• lenalidomide is not administered during the first dosing cycle. In some embodiments, lenalidomide is orally administered during any of the one or more (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) additional dosing cycles. In some embodiments, lenalidomide is orally administered during any of the ten additional dosing cycles. In some embodiments, lenalidomide is orally administered during each of the ten additional dosing cycles. In some embodiments, lenalidomide is orally administered on Days 1 -21 of each of the additional dosing cycles comprising administration of lenalidomide.
• lenalidomide is not administered on the last 7 days ( ⁇ 1 day) of any dosing cycle comprising administration of lenalidomide.
• lenalidomide is administered at a dose of about 10 mg (e.g., 10 mg ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, or ⁇ 2 mg; e.g., 10 mg).
• lenalidomide is administered at a dose of about 20 mg (e.g., 20 mg ⁇ 0.05 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, or ⁇ 4 mg; e.g., 20 mg).
• the first dosing cycle further comprises administration of a corticosteroid.
• the second dosing cycle further comprises administration of a corticosteroid.
• any of the one or more additional dosing cycles comprises administration of a corticosteroid.
• a single dose of the corticosteroid is administered to the subject prior to the administration of any dose of mosunetuzumab.
• the corticosteroid comprises dexamethasone or methylprednisolone.
• the corticosteroid is administered intravenously or orally.
• the corticosteroid comprises dexamethasone and is administered at a dose of about 20 mg (e.g., 20 mg ⁇ 0.05 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, or ⁇ 4 mg; e.g., 20 mg).
• the corticosteroid comprises methylprednisolone and is administered at a dose of about 80 mg (e.g., 80 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇ 1 .5 mg, ⁇ 2 mg, ⁇ 3 mg, ⁇ 4 mg, ⁇ 5 mg, ⁇ 6 mg, ⁇ 7 mg, ⁇ 8 mg, ⁇ 10 mg, ⁇ 12 mg, ⁇ 14 mg, or ⁇ 16 mg; e.g., 80 mg).
• 80 mg e.g. 80 mg ⁇ 0.01 mg, ⁇ 0.025 mg, ⁇ 0.05 mg, ⁇ 0.075 mg, ⁇ 0.1 mg, ⁇ 0.2 mg, ⁇ 0.3 mg, ⁇ 0.4 mg, ⁇ 0.5 mg, ⁇ 0.75 mg, ⁇ 1 mg, ⁇
• the first dosing cycle further comprises administration of an antihistamine.
• the second dosing cycle further comprises administration of an antihistamine.
• any of the one or more additional dosing cycles comprises administration of an antihistamine.
• a single dose of the antihistamine is administered to the subject prior to (e.g., 30, 35, 40, 45, 50, 60 70, 80, 90, 120, 150, 180 minutes, or more prior to) the administration of any dose of mosunetuzumab.
• the antihistamine is administered to the subject at least 30 minutes (e.g., 30, 35, 40, 45, 50, 60 70, 80, 90, 120, 150, 180 minutes, or more) prior to the administration of any dose of mosunetuzumab. In some embodiments, the antihistamine is administered orally or intravenously.
• the antihistamine comprises diphenhydramine hydrochloride and is administered at a dose of about 50-100 mg (e.g., 50-90 mg, 50-80 mg, 50-70 mg, 50-60 mg, 60-100 mg, 70-100 mg, 80-100 mg, 90-100 mg, 70- 80 mg, 60-90 mg, 60-80 mg, 70-90 mg, or 65-85 mg; e.g., about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, or about 100 mg).
• 50-100 mg e.g., 50-90 mg, 50-80 mg, 50-70 mg, 50-60 mg, 60-100 mg, 70-100 mg, 80-100 mg, 90-100 mg, 70- 80 mg, 60-90 mg, 60-80 mg, 70-90 mg, or 65-85 mg
• the first dosing cycle further comprises administration of an antipyretic.
• the second dosing cycle further comprises administration of an antipyretic.
• any of the one or more additional dosing cycles comprises administration of an anti-pyretic.
• a single dose of the anti-pyretic is administered to the subject prior to the administration of any dose of mosunetuzumab.
• the anti-pyretic is administered to the subject at least 30 minutes (e.g., 30, 35, 40, 45, 50, 60 70, 80, 90, 120, 150, 180 minutes, or more) prior to the administration of any dose of mosunetuzumab.
• the anti-pyretic is administered orally.
• the anti-pyretic comprises acetaminophen and is administered at a dose of about 500-1000 mg (e.g., 500-900 mg, 500- 800 mg, 500-700 mg, 500-600 mg, 600-1000 mg, 700-1000 mg, 800-1000 mg, 900-1000 mg, 700-800 mg, 600-900 mg, 600-800 mg, 700-900 mg, or 650-850 mg; e.g., about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg).
• 500-1000 mg e.g., 500-900 mg, 500- 800 mg, 500-700 mg, 500-600 mg, 600-1000 mg, 700-1000 mg, 800-1000 mg, 900-1000 mg, 700-800 mg, 600-900 mg, 600-800 mg, 700-900 mg, or 650-850 mg
• the first dosing cycle further comprises administration of an initial dose of a prophylactic agent against tumor lysis syndrome (TLS).
• the second dosing cycle further comprises administration of an initial dose of a prophylactic agent against TLS.
• any of the one or more additional dosing cycles comprises administration of an initial dose of a prophylactic agent against TLS.
• the initial dose of the prophylactic agent against TLS is administered to the subject prior to the administration of any dose of mosunetuzumab.
• the prophylactic agent against TLS comprises allopurinol.
• the initial dose of allopurinol is administered about 72 hours (e.g., 72 ⁇ 0.5 hours, ⁇ 1 hours, ⁇ 2 hours, ⁇ 3 hours, ⁇ 4 hours, ⁇ 8 hours, ⁇ 12 hours, or ⁇ 16 hours; e.g., 72 hours) prior to the administration of any dose of mosunetuzumab.
• additional single doses of allopurinol are administered daily for 6-10 days ( ⁇ 1 day) after the administration of the initial dose.
• the initial dose of allopurinol is about 300 mg (e.g., 300 mg ⁇ 5 mg, ⁇ 10 mg, ⁇ 15 mg, ⁇ 20 mg, ⁇ 25 mg, ⁇ 30 mg, ⁇ 45 mg, or ⁇ 60 mg; e.g., 300 mg).
• each additional single dose of allopurinol is about 300 mg (e.g., 300 mg ⁇ 5 mg, ⁇ 10 mg, ⁇ 15 mg, ⁇ 20 mg, ⁇ 25 mg, ⁇ 30 mg, ⁇ 45 mg, or ⁇ 60 mg; e.g., 300 mg).
• allopurinol is administered orally.
• the prophylactic agent against TLS comprises rasburicase.
• the initial dose of rasburicase is administered about 30 minutes (e.g., 30 ⁇ 0.5 minutes, 1 minutes, ⁇ 2 minutes, ⁇ 3 minutes, ⁇ 4 minutes, ⁇ 5 minutes, or ⁇ 6 minutes; e.g., 30 minutes) prior to the administration of any dose of mosunetuzumab.
• additional single doses of rasburicase are administered daily for 1 -5 days ( ⁇ 1 day) after the administration of the initial dose.
• the initial dose of rasburicase is about 0.2 mg/kg (e.g., 0.2 ⁇ 0.005 mg/kg, ⁇ 0.01 mg/kg, ⁇ 0.02 mg/kg, ⁇ 0.03 mg/kg, or ⁇ 0.04 mg/kg; e.g., 0.2 mg/kg).
• each additional single dose of rasburicase is about 0.2 mg/kg (e.g., 0.2 ⁇ 0.005 mg/kg, ⁇ 0.01 mg/kg, ⁇ 0.02 mg/kg, ⁇ 0.03 mg/kg, or ⁇ 0.04 mg/kg; e.g., 0.2 mg/kg).
• rasburicase is administered intravenously.
• an IL-6R antagonist may be administered to the subject treated with the methods of the invention, e.g., when the subject exhibits CRS, e.g., after being administered any dose of mosunetuzumab.
• the IL-6R antagonist is tocilizumab.
• tocilizumab is administered to the subject as a single dose of about 8 mg/kg (e.g., 8 mg/kg ⁇ 0.01 mg/kg, ⁇ 0.025 mg/kg, ⁇ 0.05 mg/kg, ⁇ 0.075 mg/kg, ⁇ 0.1 mg/kg, ⁇ 0.2 mg/kg, ⁇ 0.3 mg/kg, ⁇ 0.4 mg/kg, ⁇ 0.5 mg/kg, ⁇ 0.75 mg/kg, ⁇ 1 mg/kg, ⁇ 1 .5 mg/kg, or ⁇ 2 mg/kg; e.g., 8 mg/kg), and wherein the single dose does not exceed 800 mg.
• 8 mg/kg e.g., 8 mg/kg ⁇ 0.01 mg/kg, ⁇ 0.025 mg/kg, ⁇ 0.05 mg/kg, ⁇ 0.075 mg/kg, ⁇ 0.1 mg/kg, ⁇ 0.2 mg/kg, ⁇ 0.3 mg/kg, ⁇ 0.4 mg/kg, ⁇ 0.5 mg/kg, ⁇ 0.
• tocilizumab is administered to the subject as a single dose of about 12 mg/kg (e.g., 12 mg/kg ⁇ 0.01 mg/kg, ⁇ 0.025 mg/kg, ⁇ 0.05 mg/kg, ⁇ 0.075 mg/kg, ⁇ 0.1 mg/kg, ⁇ 0.2 mg/kg, ⁇ 0.3 mg/kg, ⁇ 0.4 mg/kg, ⁇ 0.5 mg/kg, ⁇ 0.75 mg/kg, ⁇ 1 mg/kg, ⁇ 1 .5 mg/kg, or ⁇ 2 mg/kg; e.g., 12 mg/kg), and wherein the single dose does not exceed 800 mg.
• tocilizumab is administered intravenously.
• the methods described herein may result in an acceptable safety profile for subjects having previously untreated follicular lymphoma (FL) being treated with combination therapy of mosunetuzumab and lenalidomide.
• treatment using the methods described herein that include subcutaneously administering mosunetuzumab in the context of dose-escalation dosing regimen and oral administration of lenalidomide results in a reduction (e.g., by 20% or greater, 25% or greater, 30% or greater, 35% or greater, 40% or greater, 45% or greater, 50% or greater, 55% or greater, 60% or greater, 65% or greater, 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 96% or greater, 97% or greater, 98% or greater, or 99% or greater; e.g., between 20% and 100%, between 20% and 90%, between 20% and 80%, between 20% and 70%, between 20% and 60%, between 20% and 50%, between 20% and 40%, between 20% and 30%, between 40% and 100%,
• the invention provides mosunetuzumab, a bispecific antibody that binds to CD20 and CD3, useful for treating a previously untreated follicular lymphoma (FL).
• Mosunetuzumab has an anti-CD20 arm having a first binding domain comprising the following six hypervariable regions (HVRs): (a) an HVR-H1 comprising the amino acid sequence of GYTFTSYNMH (SEQ ID NO: 1 ); (b) an HVR-H2 comprising the amino acid sequence of AIYPGNGDTSYNQKFKG (SEQ ID NO: 2); (c) an HVR-H3 comprising the amino acid sequence of VVYYSNSYWYFDV (SEQ ID NO: 3); (d) an HVR-L1 comprising the amino acid sequence of RASSSVSYMH (SEQ ID NO: 4); (e) an HVR-L2 comprising the amino acid sequence of APSNLAS (SEQ ID NO: 5); and (f) an HVR-L3 comprising the amino acid sequence of QQWSFNPPT (SEQ ID NO: 6).
• HVRs hypervariable regions
• Mosunetuzumab comprises an anti-CD20 arm comprising a first binding domain comprising the heavy chain framework regions FR-H1 , FR-H2, FR-H3, and FR-H4 comprising the sequences of SEQ ID NOs: 17-20, respectively, and the light chain framework regions FR-L1 , FR-L2, FR-L3, and FR-L4 comprising the sequences of SEQ ID NOs: 21 -24, respectively.
• Mosunetuzumab comprises an anti-CD20 arm comprising a first binding domain comprising (a) a heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO: 7; and (b) a light chain variable (VL) domain comprising the amino acid sequence o, SEQ ID NO: 8.
• Mosunetuzumab has an anti-CD3 arm having a second binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of NYYIH (SEQ ID NO: 9); (b) an HVR-H2 comprising the amino acid sequence of WIYPGDGNTKYNEKFKG (SEQ ID NO: 10); (c) an HVR-H3 comprising the amino acid sequence of DSYSNYYFDY (SEQ ID NO: 11 ); (d) an HVR-L1 comprising the amino acid sequence of KSSQSLLNSRTRKNYLA (SEQ ID NO: 12); (e) an HVR-L2 comprising the amino acid sequence of WASTRES (SEQ ID NO: 13); and (f) an HVR-L3 comprising the amino acid sequence of TQSFILRT (SEQ ID NO: 14).
• Mosunetuzumab comprises an anti-CD3 arm comprising a second binding domain comprising the heavy chain framework regions FR-H1 , FR-H2, FR-H3, and FR-H4 comprising the sequences of SEQ ID NOs: 25-28, respectively, and the light chain framework regions FR- L1 , FR-L2, FR-L3, and FR-L4 comprising the sequences of SEQ ID NOs: 29-32, respectively.
• Mosunetuzumab comprises an anti-CD3 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence having the amino acid sequence of SEQ ID NO: 15; and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 16.
• Mosunetuzumab has the International Nonproprietary Names for Pharmaceutical Substances (INN) List 1 17 (WHO Drug Information, Vol. 31 , No. 2, 2017, p. 304-305), or CAS Registry No. 1905409- 39-3, and having (1 ) an anti-CD20 arm comprising the heavy chain and light chain sequences of SEQ ID NOs: 33 and 34, respectively; and (2) an anti-CD3 arm comprising the heavy chain and light chain sequences of SEQ ID NOs: 35 and 36, respectively.
• INN International Nonproprietary Names for Pharmaceutical Substances
• Mosunetuzumab comprises (1 ) an anti-CD20 arm comprising a first binding domain comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 33 and a light chain comprising the amino acid sequence of SEQ ID NO: 34 and (2) an anti-CD3 arm comprising a second binding domain comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 35 and a light chain comprising the amino acid sequence of SEQ ID NO: 36.
• Mosunetuzumab may be produced using recombinant methods and compositions, for example, as described in U.S. Patent No. 4,816,567.
• Lenalidomide is an immunomodulatory (IMiD) imide drug that binds to cereblon, an E3 ubiquitin ligase protein (Gribben et al. J. Clin. Oncol. 33(25) :2803-281 1 , 2015).
• the immunomodulatory activity of lenalidomide is not completely understood; however, lenalidomide has been shown to enhance CD4+ and CD8+ T-cell co-stimulation, induce T-cell proliferation, and enhance IL-2 and IFN-y (Haslett et al. J. Exp. Med. 187(1 1 ):1885-1892, 1998; Davies et al. Blood 98(1 ):210-216, 2001 ).
• Lenalidomide has the CAS Registry Number 191732-72-6 and IUPAC name (3RS)-3-(4-Amino-1 - oxo-1 ,3-dihydro-2H-isoindol-2-yl)piperidine-2, 6-dione.
• Lenalidomide is also known by tradenames including REVLIMID®, linamid, and lenalid.
• Lenalidomide has the DrugBank Accession Number DB00480, PubChem CID 216326, and chemical formula C13H13N3O3.
• the methods described herein include administering mosunetuzumab and lenalidomide in combination with one or more additional therapeutic agents.
• the one or more additional therapeutic agents may prevent, reduce the rate of, or reduce the severity of cytokine release syndrome (CRS) and/or symptoms associated with CRS.
• the additional therapeutic agent used to reduce the rate or severity of CRS or prevent symptoms associated with CRS is a corticosteroid (e.g., dexamethasone (CAS#: 50-02-2), prednisone (CAS#: 53-03-2), prednisolone (CAS#: 50-42-8), or methylprednisolone (CAS#: 83-43-2)), antihistamine (e.g., diphenhydramine (CAS#: 58-73-1 ) and pharmaceutically acceptable salts thereof, e.g., diphenhydramine hydrochloride (CAS#: 147-24-0)) or an interleukin-6 receptor (IL-6R) antagonist (e.g., tocilizumab (CAS#: 375823-41 -9), sarilumab (CAS#: 1189541 -98-7
• the additional therapeutic agent is a corticosteroid.
• the corticosteroid is dexamethasone or methylprednisolone.
• the antihistamine is diphenhydramine hydrochloride.
• the anti-pyretic is acetaminophen (i.e., paracetamol) or pharmaceutically acceptable salts thereof.
• the IL-6R antagonist is tocilizumab.
• the one or more additional therapeutic agents may be used in the treatment of neutropenia.
• the additional therapeutic agents may be prevent symptoms associated with neutropenia.
• the additional therapeutic agents may reduce the rate or severity of neutropenia.
• the additional therapeutic agent is granulocyte colony-stimulating factor (G-CSF or GCSF) or colony-stimulating factor 3 (CSF 3).
• G-CSF or GCSF granulocyte colony-stimulating factor
• CSF 3 colony-stimulating factor 3
• the mRNA sequence of human G- CSF/CSF 3 includes, e.g., NCBI RefSeq No.
• NM_000759, NM_001178147, NM_172219, and NM_172220, and the protein amino acid sequence of human G-CSF/CSF 3 includes, e.g., NCBI RefSeq No. NP 000750, NP 001171618, NP_757373, and NP_757374.
• the one or more additional therapeutic agents is a prophylactic agent against, e.g., to prevent, reduce the rate of, or reduce the severity of tumor lysis syndrome (TLS).
• the prophylactic agent against TLS is allopurinol (CAS#: 315-30-0), rasburicase (ElitekTM; CAS#: 134774-45-1 ), or suitable alternatives and/or pharmaceutically acceptable salts thereof.
• the prophylactic agent against TLS reduces serum uric acid (e.g., reduces elevated uric acid levels, e.g., relative to a baseline or reference value).
• additional therapeutic agents useful in the present invention include therapeutic antibodies, such as alemtuzumab (CAMPATH®), bevacizumab (AVASTIN®, Genentech); cetuximab (ERBITUX®, Imclone); panitumumab (VECTIBIX®, Amgen), rituximab (RITUXAN®, Genentech/Biogen pie), pertuzumab (OMNITARG®, 2C4, Genentech), trastuzumab (HERCEPTIN®, Genentech), tositumomab (BEXXAR®, Corixia), and the antibody drug conjugate, gemtuzumab ozogamicin (MYLOTARG®, Wyeth).
• CAMPATH® alemtuzumab
• AVASTIN® bevacizumab
• cetuximab ERBITUX®, Imclone
• panitumumab VECTIBIX®, Amgen
• rituximab
• Additional humanized monoclonal antibodies with therapeutic potential as agents in combination with the compounds of the invention include: apolizumab, aselizumab, atlizumab, bapineuzumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizumab, numavizumab, o
• Mosunetuzumab, lenalidomide, and other therapeutic agents described herein can be used in pharmaceutical compositions and formulations.
• Pharmaceutical compositions and formulations of mosunetuzumab, lenalidomide, and/or other agents describe herein can be prepared by mixing one, two, three, or more agents having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington’s Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.
• Corticosteroids, antihistamines, anti-pyretics, prophylactic agents against TLS, and/or IL-6R antagonists may also be formulated according to standard formulation and/or manufacturing practices.
• Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum album
• Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.).
• sHASEGP soluble neutral-active hyaluronidase glycoproteins
• rHuPH20 HYLENEX®, Baxter International, Inc.
• Certain exemplary sHASEGPs and methods of use, including rHuPH20 are described in U.S. Patent Publication Nos. 2005/0260186 and 2006/0104968.
• a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
• Exemplary lyophilized antibody formulations are described in U.S. Patent No. 6,267,958.
• Aqueous antibody formulations include those described in U.S. Patent No. 6,171 ,586 and W02006/044908, the latter formulations including a histidine-acetate buffer.
• the formulation herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
• an additional therapeutic agent e.g., a chemotherapeutic agent, a cytotoxic agent, a growth inhibitory agent, and/or an anti-hormonal agent, such as those recited herein above.
• Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.
• Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methyl methacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
• colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
• Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, for example, films, or microcapsules.
• the formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
• mosunetuzumab is formulated for administration subcutaneously.
• lenalidomide is formulated for administration orally.
• dexamethasone is formulated for administration orally or intravenously.
• methylprednisolone is formulated for administration orally or intravenously.
• allopurinol is formulated for administration orally.
• rasburicase is formulated for administration intravenously.
• tocilizumab is formulated for administration intravenously.
• kits or an article of manufacture containing materials useful for the treatment, prevention, and/or diagnosis of the disorders described above.
• the kit or article of manufacture comprises a container and a label or package insert on or associated with the container.
• Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc.
• the containers may be formed from a variety of materials such as glass or plastic.
• the container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be a vial having a stopper pierceable by a hypodermic injection needle).
• At least one active agent in the composition is mosunetuzumab or lenalidomide described herein.
• the label or package insert indicates that the composition is used for treating previously untreated follicular lymphoma (FL) and further includes information related to at least one of the dosing regimens described herein. In some embodiments, the label or package insert indicates that the composition is used for treating previously untreated FL in a patient.
• the kit or article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises mosunetuzumab, lenalidomide, or both mosunetuzumab and lenalidomide; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
• the kit or article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Flinger’s solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
• Example 1 A Phase Ib/ll, Open-Label, Non-Randomized, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Mosunetuzumab in Combination with Lenalidomide in Patients with Previously Untreated Follicular Lymphoma
• Study CO41942 is an ongoing Phase Ib/ll, open-label, multicenter study, and includes evaluation of the safety, tolerability, and pharmacokinetics of subcutaneous mosunetuzumab administration in combination with lenalidomide in patients with previously untreated follicular lymphoma (FL).
• the study design of the present study is summarized in FIG. 1 .
• the study includes an expansion cohort of about 20-40 patients who are dosed with the recommended Phase 2 dosing (RP2D) of mosunetuzumab.
• R2D Phase 2 dosing
• Study treatment is administered for 12 cycles; the duration of dosing cycle (Cycle) 1 is 21 days, and the duration of Cycle 2-12 is 28 days.
• Mosunetuzumab is administered together with lenalidomide in Cycle 2 after patients complete Cycle 1 step-up dosing.
• Fluorodeoxyglucose-avid lymphoma i.e., positron emission tomography (PET)-positive lymphoma
• At least one bi-dimensionally measurable nodal lesion > 1 .5 cm in its largest dimension by PET-computed tomography (CT) scan
• at least one bi-dimensionally measurable extranodal lesion > 1 .0 cm in its largest dimension by PET-CT scan
• Adequate hematologic function (without growth factors or blood product transfusion within 14 days of first dose of study drug administration) is defined as follows:
• Treatment with systemic immunosuppressive medications including, but not limited to, prednisone, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1
• Active hepatitis B infection patients who are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive, must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR) to be eligible for study participation.
• HBV hepatitis B virus
• HCV hepatitis C virus
• HIV human immunodeficiency virus
• carcinoma in situ of the cervix carcinoma in situ of the cervix, good-prognosis ductal carcinoma in situ of the breast, basal, or squamous cell skin cancer
• autoimmune disease including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis, with treatment-free interval from immunosuppressive therapy for 12 months, may be eligible.
• cardiovascular disease e.g., New York Heart Association Class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina
• pulmonary disease such as obstructive pulmonary disease or history of bronchospasm
• liver disease including viral or other hepatitis, current alcohol abuse, or cirrhosis
• Mosunetuzumab is administered subcutaneously (SC) following a step-up dosing regimen: in Cycle 1 (21 -day dosing cycle), patients receive 5 mg on Day 1 (C1 D1 dose); 45 mg on Day 8 (C1 D2 dose); and 45 mg on Day 15 (C1 D3 dose). In Cycles 2-12 (28-day dosing cycles), patients receive 45 mg on Day 1 (C2D1 -C12D1 doses). Hospitalization is not required for patients who receive subcutaneous mosunetuzumab (based on prior clinical experience in Study GO29781 ) unless clinically indicated.
• a patient has a toxicity necessitating SC mosunetuzumab interruption for > 7 days prior to the Cycle 1 Day 8 dose, the patient is required to repeat the 5 mg dose prior to resuming the planned treatment schedule (7 days after the administration of the 5 mg dose). If dose delay results in a treatment-free interval of 6 weeks or longer, step up dosing of SC mosunetuzumab is required on Days 1 (5 mg), and 8 (45 mg) for the first cycle after the dose delay. Corticosteroid prophylaxis should be administered on days when repeat doses are administered to mitigate cytokine release syndrome (CRS) risks.
• CRS cytokine release syndrome
• Corticosteroid premedication consisting of dexamethasone 20 mg or methylprednisolone 80 mg is administered orally or intravenously (IV) prior to the administration of each mosunetuzumab dose.
• premedication with oral or IV analgesic/antipyretic e.g., 500-1 ,000 mg acetaminophen or paracetamol
• oral or IV antihistamine e.g., 50-100 mg diphenhydramine
• Premedication with analgesic/antipyretic and antihistamine occurs at least 30 minutes prior to administration of mosunetuzumab.
• Premedication is administered to all patients in Cycle 1 , and may be optional from Cycle 2 and beyond. However, if a patient experiences CRS in earlier doses, premedication with corticosteroids is administered for subsequent doses.
• TLS tumor lysis syndrome
• rasburicase a suitable alternative such as rasburicase
• Lenalidomide is administered orally (PO) 20 mg once daily on Days 1 -21 of Cycles 2-12 (28- day cycles). Lenalidomide is not administered on the last 7 days of each of the 28-day Cycles 2-12. If creatinine clearance is ⁇ 60 mL/min, lenalidomide is instead started at a dose of 10 mg/day.
• lenalidomide On the days when lenalidomide is administered with mosunetuzumab, lenalidomide is administered first, followed by subcutaneous mosunetuzumab injection. Lenalidomide is administered at approximately the same time each day. If a dose of lenalidomide is missed and it has been ⁇ 12 hours since the time of the scheduled dose, the patient is allowed to take the missed dose. If it has been > 12 hours, the dose is skipped and the next dose is taken at the regularly scheduled time. Two doses are not to be taken at the same time. If a dose is vomited, the dose is not re-taken.
• G-CSF Granulocyte colony-stimulating factor
• EORTC European Organisation [sic] for Research and Treatment of Cancer
• EORTC European Society for Medical Oncology guidelines
• Prophylactic treatment with antibiotics should be administered as per standard practice.
• Lenalidomide increases the risk of thromboembolism (TE).
• Anticoagulation prophylaxis may be given after a careful assessment of a patient’s underlying risk factors. All patients are recommended to receive daily low-dose aspirin (81 -100 mg) during lenalidomide treatment and until 28 days after the last dose of lenalidomide. Patients who are unable to tolerate aspirin, who have a history of TE, and who are at high risk of TE may receive warfarin or low-molecular-weight heparin or novel oral anticoagulant in accordance with institutional practice.
• Tocilizumab is administered when necessary to patients who experience a CRS event. Tocilizumab is administered at a dose of 8 mg/kg IV (for participants at or above 30-kg weight only) or 12 mg/kg (for participants less than 30 kg weight) for maximum of 4 doses; doses exceeding 800 mg per infusion are not recommended.
• Mosunetuzumab dosing is not modified in this study. Patients receiving mosunetuzumab who experience a Grade 4, related, non-hematologic adverse event discontinue study treatment.
• Lenalidomide dosing is modified for patients individually based on toxicity rules described below and further in detail in Table 6.
• the lenalidomide dose may be reduced in 5-mg increments (e.g., 20 mg reduced to 15 mg; 15 mg reduced to 10 mg, 10 mg reduced to 5 mg). There is no more than one dose reduction per dosing cycle. If the lenalidomide dose is reduced, re-escalation is not permitted. If lenalidomide was started at a dose of 10 mg/day for creatinine clearance > 50 but ⁇ 60 mL/min, and creatinine clearance remains above 50 mL/min after 2 cycles, the lenalidomide dose can be increased to 15 mg if the patient has tolerated therapy. Doses that were missed, due to toxicity or any other reasons, are not rescheduled or readministered.
• AE adverse event
• NSAID nonsteroidal anti-inflammatory drug
• TLS tumor lysis syndrome
• ULN upper limit of normal.
• a Dose modifications apply only to events that are considered to be related to lenalidomide. b Graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5 (NCI CTCAE Version 5.0; cancer.gov).
• Hormone therapy other than contraceptives, hormone-replacement therapy, or megestrol acetate.
• an adverse event is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution.
• An adverse event can therefore be any of the following:
• Adverse events that are related to a protocol-mandated intervention including those that occur prior to assignment of study treatment (e.g., screening invasive procedures such as biopsies)
• a serious adverse event is any adverse event that meets any of the following criteria:
• Severity refers to the intensity of an adverse event (e.g., rated as mild, moderate, or severe, or according to NCI CTCAE; cancer.gov); the event itself may be of relatively minor medical significance (e.g., severe headache without any further findings).
• infectious agent Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is considered an infectious agent.
• a transmission of an infectious agent may be suspected from clinical symptoms or laboratory findings that indicate an infection in a patient exposed to a medicinal product. This term applies only when a contamination of the study drug is suspected.
• Adverse events of special interest for mosunetuzumab include the following:
• TLS Tumor lysis syndrome
• Grade > 2 tumor inflammation or flare e.g., manifestation of signs/symptoms associated with an increase in size of known nodal or extranodal lesions by clinical or radiographic assessment, new onset, or worsening of preexisting pleural effusions
• Adverse events of special interest for lenalidomide include the following:
• the efficacy of treatment of previously untreated FL with mosunetuzumab and lenalidomide is assessed on the basis of the following endpoints using standard criteria for NHL, assessed by the investigator using the Lugano classification (Cheson BD, et al. J Clin Oncol 2014; 32:1 -9). Responses are assessed based on positron emission tomography/computer tomography (PET-CT) scans.
• PET-CT positron emission tomography/computer tomography
• CRR defined as the proportion of patients whose best overall response is a CR during the study.
• the exact 95% confidence intervals using the Clopper-Pearson method is provided.
• ORR defined as the proportion of patients whose best overall response is a CR or PR during the study. The exact 95% Cis using the Clopper-Pearson method is provided.
• DOR defined as the time from the first occurrence of a documented objective response to disease progression or relapse or death from any cause, whichever occurs first.
• the Kaplan-Meier estimate is provided.
• the Brookmeyer-Crowley method is used to construct the 95% Cl for the median DOR. Duration of response includes all patients with a CR or PR according to the investigator.
• DOCR defined as the time from the first occurrence of a documented complete response to disease progression or relapse or death from any cause, whichever occurs first.
• the Kaplan-Meier estimate is provided.
• the Brookmeyer-Crowley method is used to construct the 95% Cl for the median DOR.
• DOCR includes all patients with a CR according to the investigator.
• the plasma PK of mosunetuzumab is summarized by estimating the Cmax, Cmin, and AUC, if appropriate. These parameters are tabulated and summarized (mean, standard deviation, coefficient of variation, median, minimum, and maximum).
• Serum concentrations of lenalidomide is measured. The concentration of lenalidomide is summarized using descriptive statistics as described above.
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises orally administering between about 5 mg and about 20 mg lenalidomide daily on Days 1 -21 of the second dosing cycle.
• Mosunetuzumab for use in combination with lenalidomide for treating a subject having a previously untreated F), wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises between about 5 mg and about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• Lenalidomide for use in combination with mosunetuzumab for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises between about 5 mg and about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• mosunetuzumab in combination with lenalidomide for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises between about 5 mg and about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises between about 5 mg and about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises between about 5 mg and about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises between about 5 mg and about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• each of the one or more additional dosing cycles comprises an additional single dose of mosunetuzumab.
• mosunetuzumab for use lenalidomide for use, or use of embodiment 12, wherein the additional single dose of mosunetuzumab is about 45 mg.
• a method of treating a subject having a previously untreated FL comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises orally administering about 10 mg lenalidomide daily on Days 1 -21 of the second dosing cycle.
• Mosunetuzumab for use in combination with lenalidomide for treating a subject having a previously untreated F), wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises about 10 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• Lenalidomide for use in combination with mosunetuzumab for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises about 10 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• mosunetuzumab in combination with lenalidomide for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises about 10 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises about 10 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises about 10 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises about 10 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• a method of treating a subject having a previously untreated FL comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises orally administering about 20 mg lenalidomide daily on Days 1 -21 of the second dosing cycle.
• Mosunetuzumab for use in combination with lenalidomide for treating a subject having a previously untreated F), wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• Lenalidomide for use in combination with mosunetuzumab for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• mosunetuzumab in combination with lenalidomide for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and a second 28-day dosing cycle, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second dosing cycle comprises a single dose (C2D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about 45 mg, and
• the second dosing cycle further comprises about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of the second dosing cycle.
• a method of treating a subject having a previously untreated FL comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg, and
• the second to twelfth dosing cycles each further comprises orally administering about 10 mg lenalidomide daily on Days 1 -21 of each dosing cycle.
• Mosunetuzumab for use in combination with lenalidomide for treating a subject having a previously untreated F), wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg, and
• the second to twelfth dosing cycles each further comprises about 10 mg lenalidomide to be orally administered daily on Days 1 -21 of each dosing cycle.
• Lenalidomide for use in combination with mosunetuzumab for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg, and
• the second to twelfth dosing cycles each further comprises about 10 mg lenalidomide to be orally administered daily on Days 1 -21 of each dosing cycle.
• mosunetuzumab in combination with lenalidomide for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg, and
• the second to twelfth dosing cycles each further comprises about 10 mg lenalidomide to be orally administered daily on Days 1 -21 of each dosing cycle.
• mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg, and
• the second to twelfth dosing cycles each further comprises about 10 mg lenalidomide to be orally administered daily on Days 1 -21 of each dosing cycle.
• mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg, and
• the second to twelfth dosing cycles each further comprises about 10 mg lenalidomide to be orally administered daily on Days 1 -21 of each dosing cycle.
• mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg, and
• the second to twelfth dosing cycles each further comprises about 10 mg lenalidomide to be orally administered daily on Days 1 -21 of each dosing cycle.
• a method of treating a subject having a previously untreated FL comprising administering to the subject mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg, and
• the second to twelfth dosing cycles each further comprises orally administering about 20 mg lenalidomide daily on Days 1 -21 of each dosing cycle.
• Mosunetuzumab for use in combination with lenalidomide for treating a subject having a previously untreated F), wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg, and
• the second to twelfth dosing cycles each further comprises about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of each dosing cycle.
• Lenalidomide for use in combination with mosunetuzumab for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg
• each single dose C2D1 -C12D1 is about 45 mg
• the second to twelfth dosing cycles each further comprises about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of each dosing cycle.
• mosunetuzumab in combination with lenalidomide for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg, and
• the second to twelfth dosing cycles each further comprises about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of each dosing cycle.
• mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg, and
• the second to twelfth dosing cycles each further comprises about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of each dosing cycle.
• mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject having a previously untreated FL, wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg
• each single dose C2D1 -C12D1 is about 45 mg
• the second to twelfth dosing cycles each further comprises about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of each dosing cycle.
• mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21 -day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
• the first dosing cycle comprises a first dose (C1 D1 ), a second dose (C1 D2), and a third dose (C1 D3) of mosunetuzumab to be subcutaneously administered on Days 1 , 8, and 15, respectively, of the first dosing cycle, wherein the C1 D1 is about 5 mg, the C1 D2 is about 45 mg, and the C1 D3 is about 45 mg,
• the second to twelfth dosing cycles each comprises a single dose (C2D1 -C12D1 ) of mosunetuzumab to be subcutaneously administered on Day 1 of each dosing cycle, wherein each single dose C2D1 -C12D1 is about 45 mg, and
• the second to twelfth dosing cycles each further comprises about 20 mg lenalidomide to be orally administered daily on Days 1 -21 of each dosing cycle.51 .
• any of the one or more additional dosing cycles comprises administration of a corticosteroid.
• mosunetuzumab for use lenalidomide for use, or use of any one of embodiments 53-55, wherein a single dose of the corticosteroid is administered or is to be administered to the subject prior to the administration of any dose of mosunetuzumab.
• any of the one or more additional dosing cycles comprises administration of an antihistamine.
• mosunetuzumab for use, lenalidomide for use, or use of embodiment 64 wherein the antihistamine is administered or is to be administered to the subject at least 30 minutes prior to the administration of any dose of mosunetuzumab.
• 71 The method, mosunetuzumab for use, lenalidomide for use, or use of any one of embodiments 68-70, wherein a single dose of the anti-pyretic is administered or is to be administered to the subject prior to the administration of any dose of mosunetuzumab.
• TLS tumor lysis syndrome
• any of the one or more additional dosing cycles comprises administration of an initial dose of a prophylactic agent against TLS.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Immunology (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Genetics & Genomics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Endocrinology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=87519897

Family Applications (1)

Country Status (11)

Cited By (1)

Citations (9)

Family Cites Families (1)

• 2023
  • 2023-06-21 EP EP23748657.6A patent/EP4543546A1/en active Pending
  • 2023-06-21 KR KR1020257000914A patent/KR20250025678A/ko active Pending
  • 2023-06-21 CA CA3259327A patent/CA3259327A1/en active Pending
  • 2023-06-21 JP JP2024574565A patent/JP2025521501A/ja active Pending
  • 2023-06-21 CN CN202380047723.4A patent/CN119546334A/zh active Pending
  • 2023-06-21 WO PCT/US2023/068804 patent/WO2023250367A1/en not_active Ceased
  • 2023-06-21 TW TW112123338A patent/TWI881370B/zh active
  • 2023-06-21 US US18/338,985 patent/US20240043553A1/en active Pending
  • 2023-06-21 IL IL317679A patent/IL317679A/en unknown
  • 2023-06-21 AU AU2023286618A patent/AU2023286618A1/en active Pending
• 2024
  • 2024-12-17 MX MX2024015750A patent/MX2024015750A/es unknown

Patent Citations (9)

Non-Patent Citations (33)

Also Published As

Similar Documents

Legal Events